Paris-based healthtech startup Lucis has raised $8.5 million in seed funding to expand its preventive healthcare platform across Europe and further develop its AI-supported health analysis tools.
The round was led by General Catalyst, with participation from Y Combinator, Kima Ventures, Motier Ventures, Circle.Co, and North South Ventures. The new capital will support Lucis’ growth in its existing markets — France, the UK, Ireland, and Portugal — while enabling entry into additional European countries. The company also plans to expand its network of certified laboratories and partner physicians.
Turning Medical Test Data Into Actionable Health Insights
The company focuses on preventive health by offering regular check-ups conducted in accredited medical laboratories. Test results are reviewed by a multidisciplinary medical team and supported by AI to highlight key trends and early warning signals.
Rather than presenting users with dense laboratory reports, Lucis translates results into a structured dashboard covering more than 180 biomarkers, including cardiometabolic indicators, hormones, inflammation markers, liver and kidney function, and selected micronutrients. These metrics are monitored over time, typically every six to twelve months, to detect early signs of imbalance or chronic disease risk.
Lucis positions itself as a preventive support tool rather than a medical service. It does not replace doctor consultations, diagnoses, or prescriptions, but instead helps individuals better understand their health data and engage more proactively with healthcare professionals.
“Our goal is to help people understand what’s happening inside their bodies before symptoms appear,” said Maxime Berthelot, CEO and co-founder of Lucis. “By combining certified lab data, medical expertise, and a simple digital experience, we want to make prevention accessible without stepping into the role of physicians.”
Advertisement
Addressing Europe’s Preventive Care Gap
Chronic illnesses such as cardiovascular disease, diabetes, and metabolic disorders account for the majority of deaths in Europe. Despite this, healthcare systems remain largely reactive, often intervening only once symptoms are visible, even though early indicators may appear years earlier in blood tests.
Lucis is part of a broader shift toward proactive health management, complementing wearables and wellness tools with clinically grounded data and medical oversight. The company emphasises alignment with public health standards, avoiding self-diagnosis or consumer “health gadget” approaches.
Since launch, Lucis has already facilitated over 500,000 clinical tests across its initial markets, reflecting strong demand for a more structured and medically grounded preventive health solution.
About Lucis
Founded in 2025 in Paris by Maxime Berthelot, Baptiste Debever, and Max Guerois, Lucis is a preventive healthcare platform working with certified laboratories and medical professionals across Europe. By analysing more than 180 biomarkers and tracking health data over time, Lucis helps individuals better understand and manage their long-term health. The company currently operates in France, the UK, Ireland, and Portugal and is backed by leading global and European investors.
